During a week in which The Guardian revealed that Britain intercepted and stored webcam images from millions of people, the FDA email snooping revealed in 2012 looks relatively innocent. But Republicans investigating the program think the regulator may have violated whistleblower laws by monitoring employees' emails.
Two years after press reports revealed that the FDA was extensively monitoring communications by some of its employees, a congressional committee has announced its verdict: The agency overstepped its authority--and may have broken laws meant to protect whistleblowers.
The FDA may have gone too far and violated federal law when it chose to monitor 6 scientists who made public their safety concerns about medical devices approved at the agency, a congressional investigation has concluded.
A case involving a medical device company led to a U.S. Tax Court decision determining that whistle-blower awards must be taxed as ordinary income.
After a big U.S. Justice Department settlement--after the speeches, the press releases, the commentary--attention invariably turns to the people who first blew the whistle. It's no different in the case of Johnson & Johnson, which this week announced a $2.2 billion settlement and misdemeanor plea in a longstanding probe of its Risperdal marketing.
The latest report on healthcare fraud settlements is out, this time from Taxpayers Against Fraud. And this time, as usual, Big Pharma features prominently. The anti-fraud group regularly totes up whistleblower settlements with federal and state governments, and we all know that drugmaker payments account for billions.
Another Chinese whistleblower has targeted Big Pharma. This time, the bribery allegations involve Eli Lilly, and 30 million yuan in purported kickbacks to Chinese doctors. That's about $4.9 million, or 1% of the amount GlaxoSmithKline allegedly spread around, but if the previous pattern holds, China's government watchdogs will officially follow up on the media report.
Big Pharma, beware of your former (and possibly current) employees in China. Novartis is the latest drugmaker to be fingered for bribery by an anonymous whistleblower, just a few days after Sanofi got the same treatment. And Chinese officials say they're stepping up their pharma investigation even further.
Sanofi has joined GlaxoSmithKline under China's official corruption microscope. According to the state news service Xinhua, authorities are investigating allegations that the French drugmaker bribed more than 500 doctors.
Sanofi has joined GlaxoSmithKline in facing bribery allegations in China. According to a Chinese newspaper, the whistleblower says Sanofi paid 1.7 million yuan in bribes to 503 doctors around the country.